WallStSmart

Aclarion Inc (ACON)vsMiniMed Group, Inc. Common Stock (MMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 4584491% more annual revenue ($2.89B vs $62,950). ACON leads profitability with a 0.0% profit margin vs -7.3%. MMED earns a higher WallStSmart Score of 37/100 (F).

ACON

Avoid

33

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 4/9

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACON2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
76.1%10/10

Revenue surging 76.1% year-over-year

MMED0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ACON4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.58M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-88.3%2/10

ROE of -88.3% — below average capital efficiency

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ACON

The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 76.1% demonstrates continued momentum.

Bull Case : MMED

Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : ACON

The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Key Dynamics to Monitor

ACON profiles as a hypergrowth stock while MMED is a turnaround play — different risk/reward profiles.

ACON is growing revenue faster at 76.1% — sustainability is the question.

ACON generates stronger free cash flow (-2M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MMED scores higher overall (37/100 vs 33/100) and 13.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclarion Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Aclarion Inc (ACON) is an innovative healthcare technology company specializing in non-invasive diagnostic solutions that harness advanced data analytics and machine learning. By optimizing treatment pathways for musculoskeletal conditions, Aclarion delivers actionable insights derived from cutting-edge imaging techniques. Positioned at the forefront of the digital health sector, the company is addressing significant challenges in patient management while enhancing outcomes and reducing costs. Aclarion is well-positioned to capitalize on the growing demand for effective diagnostic tools in a dynamic healthcare landscape.

Visit Website →

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Want to dig deeper into these stocks?